The Spectrum of Mast Cell Activation Syndromes

1. Kitamura, Y., K. Oboki, and A. Ito, Molecular mechanisms of mast cell  development. Immunol Allergy Clin North Am, 2006. 26(3): p. 387-405; v. 2

2. Theoharides, T.C., P. Valent, and C. Akin, Mast Cells, Mastocytosis, and Related  Disorders. N Engl J Med, 2015. 373(2): p. 163-72. 

3. Cruse, G., D.D. Metcalfe, and A. Olivera, Functional deregulation of KIT: link to  mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin  North Am, 2014. 34(2): p. 219-37. 

4. Tsai, M., P. Valent, and S.J. Galli, KIT as a master regulator of the mast cell  lineage. J Allergy Clin Immunol, 2022. 149(6): p. 1845-1854. 

5. Khan, B.Q. and S.F. Kemp, Pathophysiology of anaphylaxis. Curr Opin Allergy  Clin Immunol, 2011. 11(4): p. 319-25. 

6. Ono, E., et al., Increased production of cysteinyl leukotrienes and prostaglandin  D2 during human anaphylaxis. Clin Exp Allergy, 2009. 39(1): p. 72-80. 7. Valent, P., et al., Diagnosis, Classification and Management of Mast Cell  Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci,  2020. 21(23). 

8. Lieberman, P., Middleton's Allergy: Principles and Practice, Seventh Edition.  Anaphylaxis, Chapter 59., ed. N.F. Adkinson, et al. Vol. 2. 2010, Philadelphia,  PA: Elsevier Inc. 

9. Weiler, C.R., et al., AAAAI Mast Cell Disorders Committee Work Group Report:  Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin  Immunol, 2019. 144(4): p. 883-896. 

10. Valent, P., et al., Definitions, criteria and global classification of mast cell  disorders with special reference to mast cell activation syndromes: a consensus  proposal. Int Arch Allergy Immunol, 2012. 157(3): p. 215-25. 

11. Sonneck, K., et al., Diagnostic and subdiagnostic accumulation of mast cells in  the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation  syndrome. Int Arch Allergy Immunol, 2007. 142(2): p. 158-64. 

12. Valent, P., et al., Proposed Diagnostic Algorithm for Patients with Suspected  Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract, 2019. 7(4): p.  1125-1133 e1. 

13. Valent, P., et al., Updated Diagnostic Criteria and Classification of Mast Cell  Disorders: A Consensus Proposal. Hemasphere, 2021. 5(11): p. e646. 

14. Valent, P., et al., Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold  Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation  Syndrome. Int Arch Allergy Immunol, 2019. 180(1): p. 44-51. 

15. Mateja, A., et al., Defining baseline variability of serum tryptase levels improves  accuracy in identifying anaphylaxis. J Allergy Clin Immunol, 2022. 149(3): p.  1010-1017 e10. 

16. Pongdee, T. and M. Castells, Elevated Tryptase: Conditions and Pitfalls. J  Allergy Clin Immunol Pract, 2022. 10(9): p. 2436-2437. 

17. Akin, C., Mast cell activation disorders. J Allergy Clin Immunol Pract, 2014.  2(3): p. 252-7 e1; quiz 258.

18. Galvan-Blasco, P., J. Gil-Serrano, and A. Sala-Cunill, New Biomarkers in  Anaphylaxis (Beyond Tryptase). Curr Treat Options Allergy, 2022. 9(4): p. 303- 322. 

19. Nakamura, Y., et al., Regulation of plasma histamine levels by the mast cell clock  and its modulation by stress. Sci Rep, 2017. 7: p. 39934. 

20. Pardanani, A., Systemic mastocytosis in adults: 2017 update on diagnosis, risk  stratification and management. Am J Hematol, 2016. 91(11): p. 1146-1159. 21. Jackson, C.W., et al., Mastocytosis and Mast Cell Activation Disorders: Clearing  the Air. Int J Mol Sci, 2021. 22(20). 

22. Theoharides, T.C., P. Valent, and C. Akin, Mast Cells, Mastocytosis, and Related  Disorders. N Engl J Med, 2015. 373(19): p. 1885-6. 

23. Valent, P., C. Akin, and D.D. Metcalfe, Mastocytosis: 2016 updated WHO  classification and novel emerging treatment concepts. Blood, 2017. 129(11): p.  1420-1427. 

24. Horny, H.P., Metcalfe, D.D., Bennett, J.M., Bain, B.J., Akin C., Escribano, L.,  Valent, P. , ed. Mastocytosis. 4th ed. WHO classification of tumours of  haematopoietic and lymphoid tissues, ed. S.H. Swerdlow. 2008, IARC Press:  Lyon, France. 54-63. 

25. Arock, M., et al., KIT mutation analysis in mast cell neoplasms: recommendations  of the European Competence Network on Mastocytosis. Leukemia, 2015. 29(6): p.  1223-32. 

26. Nagata, H., et al., Identification of a point mutation in the catalytic domain of the  protooncogene c-kit in peripheral blood mononuclear cells of patients who have  mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A,  1995. 92(23): p. 10560-4. 

27. Worobec, A.S., et al., Clinical correlates of the presence of the Asp816Val c-kit  mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer, 1998. 83(10): p. 2120-9. 

28. Costa, A., et al., Systemic mastocytosis: 2023 update on diagnosis and  management in adults. Expert Opin Emerg Drugs, 2023. 28(3): p. 153-165. 29. Tefferi, A. and A. Pardanani, Targeted therapy in KITD816V-positive  mastocytosis: waiting for proof-of-principle. Leuk Lymphoma, 2010. 51(3): p.  360-2. 

30. Akin, C. and P. Valent, Diagnostic criteria and classification of mastocytosis in  2014. Immunol Allergy Clin North Am, 2014. 34(2): p. 207-18. 

31. Escribano, L., et al., Prognosis in adult indolent systemic mastocytosis: a long term study of the Spanish Network on Mastocytosis in a series of 145 patients. J  Allergy Clin Immunol, 2009. 124(3): p. 514-21. 

32. Valent, P., et al., Refined diagnostic criteria and classification of mast cell  leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol, 2014. 25(9): p. 1691-700. 

33. Jennings, S., et al., The Mastocytosis Society survey on mast cell disorders:  patient experiences and perceptions. J Allergy Clin Immunol Pract, 2014. 2(1): p.  70-6. 

34. Hartmann, K., et al., Cutaneous manifestations in patients with mastocytosis:  Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European  Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol, 2016.  137(1): p. 35-45. 

35. Valent, P., et al., Standards and standardization in mastocytosis: consensus  statements on diagnostics, treatment recommendations and response criteria. Eur  J Clin Invest, 2007. 37(6): p. 435-53. 

36. Gotlib, J., et al., Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid, 2023. 2(6): p. EVIDoa2200339. 

37. Piris-Villaespesa, M. and I. Alvarez-Twose, Systemic Mastocytosis: Following the  Tyrosine Kinase Inhibition Roadmap. Front Pharmacol, 2020. 11: p. 443. 

38. Akin, C., P. Valent, and D.D. Metcalfe, Mast cell activation syndrome: Proposed  diagnostic criteria. J Allergy Clin Immunol, 2010. 126(6): p. 1099-104 e4. 

39. Kacar, M., et al., Clonal mast cell disorders and hereditary alpha-tryptasemia as  risk factors for anaphylaxis. Clin Exp Allergy, 2023. 53(4): p. 392-404. 

40. Gulen, T. and C. Akin, Idiopathic Anaphylaxis: a Perplexing Diagnostic  Challenge for Allergists. Curr Allergy Asthma Rep, 2021. 21(2): p. 11. 

41. Sampson, H.A., et al., Second symposium on the definition and management of  anaphylaxis: summary report--Second National Institute of Allergy and Infectious  Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin  Immunol, 2006. 117(2): p. 391-7. 

42. Lyons, J.J., Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical  Features. Immunol Allergy Clin North Am, 2018. 38(3): p. 483-495.

 43. Gonzalez-Quintela, A., et al., Factors influencing serum total tryptase  concentrations in a general adult population. Clin Chem Lab Med, 2010. 48(5):  p. 701-6. 

44. Sirvent, A.E., et al., Serum tryptase levels and markers of renal dysfunction in a  population with chronic kidney disease. J Nephrol, 2010. 23(3): p. 282-90. 

45. Robey, R.C., et al., Hereditary Alpha-Tryptasemia: UK Prevalence and  Variability in Disease Expression. J Allergy Clin Immunol Pract, 2020. 8(10): p.  3549-3556. 

46. Lyons, J.J., et al., Heritable risk for severe anaphylaxis associated with increased  alpha-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin  Immunol, 2021. 147(2): p. 622-632. 

47. Greiner, G., et al., Hereditary alpha tryptasemia is a valid genetic biomarker for  severe mediator-related symptoms in mastocytosis. Blood, 2021. 137(2): p. 238- 247. 

48. Fellinger, C., et al., Clinical characteristics and risk profile of patients with  elevated baseline serum tryptase. Allergol Immunopathol (Madr), 2014. 42(6): p.  544-52. 

49. Michel, M., C. Klingebiel, and J. Vitte, Tryptase in type I hypersensitivity. Ann  Allergy Asthma Immunol, 2023. 130(2): p. 169-177. 

50. Lyons, J.J., et al., Elevated basal serum tryptase identifies a multisystem disorder  associated with increased TPSAB1 copy number. Nat Genet, 2016. 48(12): p.  1564-1569. 

51. Lyons, J.J., et al., Mendelian inheritance of elevated serum tryptase associated  with atopy and connective tissue abnormalities. J Allergy Clin Immunol, 2014.  133(5): p. 1471-4. 

52. Saito, Y.A., P. Schoenfeld, and G.R. Locke, 3rd, The epidemiology of irritable  bowel syndrome in North America: a systematic review. Am J Gastroenterol,  2002. 97(8): p. 1910-5. 

53. Remvig, L., D.V. Jensen, and R.C. Ward, Epidemiology of general joint  hypermobility and basis for the proposed criteria for benign joint hypermobility  syndrome: review of the literature. J Rheumatol, 2007. 34(4): p. 804-9. 

54. Luskin, K.T., A.A. White, and J.J. Lyons, The Genetic Basis and Clinical Impact  of Hereditary Alpha-Tryptasemia. J Allergy Clin Immunol Pract, 2021. 9(6): p.  2235-2242. 

55. Chollet, M.B. and C. Akin, Hereditary alpha tryptasemia is not associated with  specific clinical phenotypes. J Allergy Clin Immunol, 2022. 149(2): p. 728-735  e2. 

56. Mendoza Alvarez, L.B., et al., Clinical response to omalizumab in patients with  hereditary alpha-tryptasemia. Ann Allergy Asthma Immunol, 2020. 124(1): p.  99-100 e1. 

57. Castells, M., D.D. Metcalfe, and L. Escribano, Diagnosis and treatment of  cutaneous mastocytosis in children: practical recommendations. Am J Clin  Dermatol, 2011. 12(4): p. 259-70. 

58. Meni, C., et al., Paediatric mastocytosis: a systematic review of 1747 cases. Br J  Dermatol, 2015. 172(3): p. 642-51. 

59. Caplan, R.M., The natural course of urticaria pigmentosa. Analysis and follow-up  of 112 cases. Arch Dermatol, 1963. 87: p. 146-57. 

60. Weber, F.P., Urticaria Pigmentosa (telangiectatic variety) in an Adult. Proc R  Soc Med, 1932. 25(5): p. 665-6. 

61. Carter, M.C., et al., Assessment of clinical findings, tryptase levels, and bone  marrow histopathology in the management of pediatric mastocytosis. J Allergy  Clin Immunol, 2015. 136(6): p. 1673-79 e1-3. 

62. Sarkany, R.P., B.E. Monk, and S.E. Handfield-Jones, Telangiectasia macularis  eruptiva perstans: a case report and review of the literature. Clin Exp Dermatol,  1998. 23(1): p. 38-9. 

63. Weber, F.P., Telangiectasia Macularis Eruptiva Perstans-probably a  telangiectatic variety of urticaria pigmentosa in an adult. Proc R Soc Med, 1930.  24(2): p. 96-7. 

64. Williams, K.W., et al., Telangiectasia macularis eruptiva perstans or highly  vascularized urticaria pigmentosa? J Allergy Clin Immunol Pract, 2014. 2(6): p.  813-5. 

65. Ben-Amitai, D., A. Metzker, and H.A. Cohen, Pediatric cutaneous mastocytosis:  a review of 180 patients. Isr Med Assoc J, 2005. 7(5): p. 320-2. 

66. Verbov, J.L. and P.F. Borrie, Diffuse cutaneous mastocytosis. Br J Dermatol,  1971. 84(2): p. 190-1. 

67. Nemat, K. and S. Abraham, Cutaneous mastocytosis in childhood. Allergol  Select, 2022. 6: p. 1-10.

68. Brockow, K., et al., Challenges in the Diagnosis of Cutaneous Mastocytosis. Diagnostics (Basel), 2024. 14(2). 

69. Matito, A. and M. Carter, Cutaneous and systemic mastocytosis in children: a risk  factor for anaphylaxis? Curr Allergy Asthma Rep, 2015. 15(5): p. 22. 

70. Meni, C., et al., Paediatric mastocytosis: long-term follow-up of 53 patients with  whole sequencing of KIT. A prospective study. Br J Dermatol, 2018. 179(4): p.  925-932. 

71. Sandru, F., et al., Cutaneous Mastocytosis in Childhood-Update from the  Literature. J Clin Med, 2021. 10(7). 

72. Czarny, J., et al., Cutaneous mastocytosis treatment: strategies, limitations and  perspectives. Advances in Dermatology and Allergology, 2018. 35(6): p. 541-545.